E-LIB Suche - Ergebnisse für: Špicka, Ivan

1

Isatuximab plus carfilzomib–dexamethasone versus carfilzomi..:

Yong, Kwee ; Martin, Thomas ; Dimopoulos, Meletios-Athanasios...
The Lancet Haematology. , 2024

Link: https://doi.org/10.1016/..

2

A.R.R.O.W.2: Once- vs twice-weekly carfilzomib, lenalidomid..:

Dimopoulos, Meletios-Athanasios A. ; Coriu, Daniel ; Delimpasi, Sosana...
Blood Advances. , 2024

Link: https://doi.org/10.1182/..

3

Nivolumab, Pomalidomide, and Elotuzumab Combination Regimen..:

Oriol, Albert ; Hájek, Roman ; Spicka, Ivan...
Clinical Lymphoma Myeloma and Leukemia. , 2024

Link: https://doi.org/10.1016/..

4

Isatuximab-pomalidomide-dexamethasone versus pomalidomide-d..:

Richardson, Paul G. ; Perrot, Aurore ; Miguel, Jesus San...
Haematologica. , 2024

Link: https://doi.org/10.3324/..

5

An open‐label, first‐in‐human, single agent, dose escalatio..:

Kapoor, Prashant ; Nathwani, Nitya ; Jelinek, Tomas...
European Journal of Haematology. , 2024

Link: https://doi.org/10.1111/..

6

Isatuximab in combination with carfilzomib and dexamethason..:

Facon, Thierry ; Moreau, Philippe ; Špicka, Ivan...
Hematological Oncology. 42 (2024) 2 - p. , 2024

Link: https://doi.org/10.1002/..

7

Health-related quality of life in relapsed/refractory multi..:

Schjesvold, Fredrik H. ; Ludwig, Heinz ; Delimpasi, Sossana...
Haematologica. , 2024

Link: https://doi.org/10.3324/..

8

P-159 Lenalidomide maintenance in R2-ISS stratified multipl..:

Radocha, Jakub ; Jungova, Alexandra ; Pour, Ludek...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S122-S123 , 2023

Link: https://doi.org/10.1016/..

9

POSTER: MM-182 Allocation and Validation of the Second Revi..:

Perrot, Aurore ; Richardson, Paul ; Mikhael, Joseph...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S216 , 2023

Link: https://doi.org/10.1016/..

10

Selinexor-Based Triplet Regimens in Patients With Multiple ..:

Schiller, Gary J. ; Lipe, Brea C. ; Bahlis, Nizar J....
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) 9 - p. e286-e296.e4 , 2023

Link: https://doi.org/10.1016/..

11

P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF T..:

Perrot, Aurore ; Richardson, Paul ; Mikhael, Joseph...
HemaSphere. 7 (2023) S3 - p. e3398301 , 2023

Link: https://doi.org/10.1097/..

12

Efficacy and safety of melflufen plus daratumumab and dexam..:

Pour, Luděk ; Szarejko, Monika ; Bila, Jelena...
Haematologica. 109 (2023) 3 - p. 895-905 , 2023

Link: https://doi.org/10.3324/..

13

Personalised progression prediction in patients with monocl..:

Cowan, Annie ; Ferrari, Federico ; Freeman, Samuel S...
The Lancet Haematology. 10 (2023) 3 - p. e203-e212 , 2023

Link: https://doi.org/10.1016/..

14

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFIL..:

Arslan, Ecenur Guder ; Yong, Kwee ; Martın, Thomas...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S14-S15 , 2023

Link: https://doi.org/10.1016/..

15

Clinical characteristics and outcomes in risk-stratified pa..:

Sandecka, Viera ; Popkova, Tereza ; Stork, Martin...
Blood Cancer Journal. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..